Assertio Therapeutics, Inc (ASRT) is a publicly traded company in the Unknown sector. Across all available filings, 26 corporate insiders have executed 264 transactions totaling $7.2M, demonstrating a bearish sentiment with -$6.4M in net insider flow. The most recent transaction on Feb 21, 2026 involved a transaction of 1,143 shares valued at $0.
No significant insider buying has been recorded for ASRT in the recent period.
No significant insider selling has been recorded for ASRT in the recent period.
Based on recent SEC filings, insider sentiment for ASRT is bearish with an Insider Alignment Score of 6/100 and a net flow of -$6.4M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Assertio Therapeutics, Inc (ASRT) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 26 insiders are actively trading ASRT stock, having executed 264 transactions in the past 90 days. The most active insider is Daniel A. Peisert (Executive), who has made 63 transactions totaling $4.4M.
Get notified when executives and directors at ASRT file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 21, 2026 | Schwichtenberg Paul | President and COO | Option Exercise | 1,143 | $N/A | $0 | C-Suite |
| Feb 21, 2026 | Schwichtenberg Paul | President and COO | Payment | 566 | $11.84 | $6.7K | C-Suite |
| Feb 21, 2026 | Schwichtenberg Paul | President and COO | Option Exercise | 1,143 | $N/A | $0 | C-Suite |
| Feb 21, 2026 | Patel Ajay | EVP and CFO | Option Exercise | 1,143 | $N/A | $0 | C-Suite |
| Feb 21, 2026 | Patel Ajay | EVP and CFO | Payment | 566 | $11.84 | $6.7K | C-Suite |
| Feb 21, 2026 | Patel Ajay | EVP and CFO | Option Exercise | 1,143 | $N/A | $0 | C-Suite |
| Feb 21, 2026 | Schlessinger Sam | EVP, General Counsel | Option Exercise | 1,143 | $N/A | $0 | |
| Feb 21, 2026 | Schlessinger Sam | EVP, General Counsel | Payment | 510 | $11.84 | $6.0K | |
| Feb 21, 2026 | Schlessinger Sam | EVP, General Counsel | Option Exercise | 1,143 | $N/A | $0 | |
| Feb 18, 2026 | Patel Ajay | EVP and CFO | Option Exercise | 2,778 | $N/A | $0 | C-Suite |
| Feb 18, 2026 | Patel Ajay | EVP and CFO | Payment | 1,377 | $11.87 | $16.3K | C-Suite |
| Feb 18, 2026 | Patel Ajay | EVP and CFO | Option Exercise | 2,778 | $N/A | $0 | C-Suite |
| Feb 18, 2026 | Schwichtenberg Paul | President and COO | Option Exercise | 2,778 | $N/A | $0 | C-Suite |
| Feb 18, 2026 | Schwichtenberg Paul | President and COO | Payment | 1,377 | $11.87 | $16.3K | C-Suite |
| Feb 18, 2026 | Schwichtenberg Paul | President and COO | Option Exercise | 2,778 | $N/A | $0 | C-Suite |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 24 | $6.8M | 43.8% |
Payment(F) | 74 | $5.7M | 36.7% |
Disposition(D) | 4 | $2.6M | 16.8% |
Purchase(P) | 21 | $415.5K | 2.7% |
Exercise(M) | 103 | $22.4K | 0.1% |
Award(A) | 38 | $0 | 0.0% |
Insider selling pressure at Assertio Therapeutics, Inc has increased, with 26 insiders executing 264 transactions across all time. Total sales of $6.8M significantly outpace purchases of $415.5K, resulting in a net outflow of $6.4M. This selling activity appears largely discretionary, which may warrant closer attention from investors.